Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totalling 4,330,000 shares, an increase of 25.1% from the September 30th total of 3,460,000 shares. Based on an average daily volume of 577,200 shares, the short-interest ratio is presently 7.5 days. Currently, 10.7% of the company's stock are short sold.

Insider Activity at Janux Therapeutics

In other news, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of the stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $50.02, for a total transaction of $92,186.86. Following the completion of the transaction, the insider now directly owns 6,371 shares in the company, valued at $318,677.42. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Andrew Hollman Meyer sold 50,000 shares of the business's stock in a transaction on Friday, September 27th. The shares were sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the transaction, the insider now directly owns 67,592 shares in the company, valued at approximately $3,106,528.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of Janux Therapeutics stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $50.02, for a total transaction of $92,186.86. Following the completion of the transaction, the insider now directly owns 6,371 shares of the company's stock, valued at approximately $318,677.42. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 395,610 shares of company stock valued at $17,950,166. Corporate insiders own 35.40% of the company's stock.

Institutional Trading of Janux Therapeutics

Several large investors have recently modified their holdings of JANX. Capstone Investment Advisors LLC acquired a new position in Janux Therapeutics in the first quarter valued at about $1,969,000. Janus Henderson Group PLC increased its holdings in Janux Therapeutics by 1.8% in the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company's stock valued at $73,961,000 after buying an additional 34,069 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of Janux Therapeutics in the 1st quarter valued at approximately $739,000. Virtu Financial LLC bought a new stake in shares of Janux Therapeutics during the 1st quarter worth approximately $609,000. Finally, Vanguard Group Inc. boosted its position in shares of Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company's stock worth $51,127,000 after acquiring an additional 378,477 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Price Performance

Janux Therapeutics stock traded up $1.74 during midday trading on Wednesday, hitting $55.95. The company's stock had a trading volume of 529,481 shares, compared to its average volume of 713,510. The company has a 50-day moving average price of $47.50 and a two-hundred day moving average price of $46.04. Janux Therapeutics has a 1-year low of $5.65 and a 1-year high of $65.60. The company has a market cap of $2.90 billion, a price-to-earnings ratio of -45.58 and a beta of 3.54.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The business had revenue of $8.90 million during the quarter, compared to analysts' expectations of $0.77 million. The firm's revenue for the quarter was up 709.1% on a year-over-year basis. Sell-side analysts forecast that Janux Therapeutics will post -1.18 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on JANX. Stifel Nicolaus initiated coverage on Janux Therapeutics in a research report on Friday, September 6th. They set a "buy" rating and a $70.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $63.00 target price on shares of Janux Therapeutics in a report on Monday, August 19th. Wedbush reaffirmed an "outperform" rating and set a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Scotiabank dropped their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating on the stock in a research report on Friday, August 9th. Finally, UBS Group initiated coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a "buy" rating and a $69.00 price target on the stock. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $66.44.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.